A hemolytic anti-LKE associated with a rare LKE-negative, "weak P" red blood cell phenotype: alloanti-LKE and alloanti-P recognize galactosylgloboside and monosialogalactosylgloboside (LKE) antigens.

Background: "Weak P" is a rare red blood cell (RBC) phenotype, characterized by a global decrease in P(k) and P antigens. We now describe a second weak P individual who also typed LKE-negative (LKE-N) and possessed a clinically significant anti-LKE.

Study Design And Methods: Patient RBCs and plasma were examined by standard serology and flow cytometry.

Rh discrepancies caused by variable reactivity of partial and weak D types with different serologic techniques.

Background: RhD discrepancies between current and historical results are problematic to resolve. The investigation of 10 discrepancies is reported here.

Study Design: Samples identified were those that reacted by automated gel technology and were negative with an FDA-approved reagent.

Case report and literature review: transient Inab phenotype and an agglutinating anti-IFC in a patient with a gastrointestinal problem.

Background: The Inab phenotype is a rare deficiency of all Cromer antigens. These antigens are carried on the decay-accelerating factor (DAF, CD55) molecule that is attached to the red blood cell (RBC) membrane by a glycosylphosphatidylinositol (GPI) anchor. Although typically inherited, an acquired and transient form of the Inab phenotype also exists.

Persistence of cefotetan on red blood cells.

Background: Cefotetan can cause severe immune hemolytic anemia that may persist long after the drug is discontinued. To study the binding of cefotetan to RBCs, patients who received cefotetan were followed and tested for the presence of antibody to cefotetan.

Study Design And Methods: Patients receiving cefotetan were identified from pharmacy and nursing records.